open us. you, will our .
Beginning Q&A. thank Thank recent Then results trial. and you Phase up James, our program, with we review development today's all achievements ASPIRE discussing the for by call will global joining upcoming clinical milestones. financial Sue I for call and III our start our clinical before
SBP-XXX that third or with were with ivospemin, safety without June in untreated evaluating the Data recommended modification, or study marking review. pancreatic continuation positive DSMB, and patients excited ductal metastatic is in adenocarcinoma. We Safety Monitoring the nab-paclitaxel announce for Board, consecutive combination Aspire independent to gemcitabine
patients At November reached XXX XXX database that XX, that had we compared to XXXX. time, safety patients shared the on
approximately XXXX. proceeding quarter in patients ASPIRE first January, of As sites you may to recall, initially the enrollment faster surpassed be by of anticipated. and enrolling, XXX the for we enrollment expectation full XX%, actively than completed open all With reiterate our
due events initially for half announced With trial occurred. middle interim regimen, than ASPIRE to analysis the occur the median before encouraging in be the a Consequently, XXXX April, gemcitabine and which for conducted. ductal benefit interim analysis relatively less of the expected can modest suggesting now total the approval metastatic survival interim potential death respect of XX% to that to in of XXXX death data, [indiscernible] X.X-month the treating FDA's or expected interim nab-paclitaxel. to This the compared development of ASPIRE early follows ivospemin is trial's had we prolonged event the improvement in requires the primarily patients pancreatic survival, projected the or analysis required adenocarcinoma. of demonstrated In overall
remains metastatic care XX still survival milestone, months, need of pancreatic underscoring critical SBP-XXX, regulatory approved median this of believe benefits regimen nab-paclitaxel outperform therapies. of cancer effective to ASPIRE and for treatment. incremental promise. prognosis this indications that or grim With holds with the suggesting the recently with the combined Despite under gemcitabine context, trial we ivospemin, early potential standard In the more
metastatic an ivospemin Given regulatory anticipate approval. eagerly the landscape the commitment in it to current landscape that facing treatment the FDA for pancreatic signal favorably which QX results in expect we position interim this may study formidable XXXX, remains steadfast turning for could in disease. of awaits its company cancer, the this a transformative The in we and efficacy potential patients point
a continue consensus its adnomanous plan with Our program progress polyposis EMA optimize and value. FAP global reaching community. we FAP the plan, exploring commitment remains we the FDA, work on to strategies to advancing the as strong closely familial to program, Upon while to a registration or this
and III are a study second [indiscernible] Regarding prevention for enrollment investigating high-risk of concluded. colorectal Phase trial, has the the PACES adenoma pleased we cancers, primary
previously data the [indiscernible] to through treated X the event readout has half by conducted reduce the stages This NCI in of successfully the by study study by the futility Oncology for Group, second supported colorectal XXXX. the analysis, of passing adenomas cancers X-year the cancer. second X potential rate With or land in expect we primary Southwest SWOG, and patients
obtained neuroblastoma program. in studies. from place sale the additional $XXX,XXX the monetization April, of sales the eflornithine additional received II assets Phase from U.S. In later to of saw milestones pediatric in focus an Shifting years. we We
December, approval first [indiscernible] secured representing reaches polymene-targeted worth US positioned approval further receive to NDA in reiterating for that FDA payments. It's As [indiscernible] is of FDA key the approval WorldMeds US WorldMeds milestones, for its validate cancer financial only as but Panbela This we benefits in role therapy provides other progress therapy also polymenes potential our serves the not continue cancer to to programs. a indication. in of to
X:X our open in participating conducted diabetes supported actively also X of by which the under enrolling of a and to have We are School and Medicine recruiting multicenter with a interim is a II ratio, Phase analysis double-blind, metastatic with patients. randomization castration-resistant year. patients agreement take trial expected study now trial and centers into prostate The of clinical is type entered eflornithine All X study place cancer, JDRF. for leadership Indiana Phase an placebo-controlled University II eflornithine next
Medicine year. Furthermore, this we in which University cancer, to Phase the planning a we ivospemin of in aim trial to during in half latter are of the assess process platinum-resistant ovarian of collaboration with Hopkins II Johns School initiate
April to we launch as with Cancer additional a our and In of American Association Research as assess modulators presented The ivospemin polymemetabolism immune ovarian cancer in basis part investigations latter up clinical year. trials this in showcasing Upcoming efficacy Annual modulator the gear we polymimetabolism cancer. ovarian in data are to AACR robust program a offer modulators. designed fact, conjunction encouraging Meeting, in or preclinical a for at ivospemin's the poster for
we development, I have Phase X programs. In
the of Our trial initiate this our in Last, neoadjuvant year. is look Phase and with pancreatic half second for we and I/II stick looking We in initiating screening non-small Center clinical a patients. collaboration patient open the to this enrolling II cell front, investigator-initiated the cancer to and XX year Moffit Phase forward first XXXX. are lung mutant on Cancer trial
we program research efforts. Cancer commitment preclinical addition to of bispecific and to preclinical are an initiative are antibodies stage this investigate and T Center This benefits is also preclinical therapy potential Anderson clinical programs, goal progress approaches inhibitor treatment to collaborating in using our clinical The In polymene our the innovative monoclonal cell models. development of metabolic demonstrates our exploring cancer complements treatment. on we combining CAR primary with ongoing making work project. with to MD our Currently,
gastric trial in results we were premalignant in eflornithine Latin excited Additionally, at conference. Phase and patients our incidence Week presented Disease of IIa that Cancer oral University Vanderbilt National collaborators the Institute. by efficacy high a at The Digestive the of with Medical of clinical the Center titled highlighted presentation the the conditions areas placebo-controlled, in announce of safety randomized recent findings June, America, funded Evaluation to
findings study of pathway targeting patients infection-associated reduced term treatment. cancer, long cancer. in for particularly prevention DNA eflornithine, and the the that our tolerated of and treatment The developing gastric safe, in component underscore both well potential key high pain risk for demonstrated damage after a completing These with pathway approach with polymine of patients
We through area. are collaboration progress forward look and our made with the this to further thrilled in this research advancing
patient projected for of interim ovarian cell quarter XXXX, completion the trial, our include: the the milestones III IIb the cancer as obtaining Phase trial, final SAP; the neoadjuvant first in second half cancer trial data, Phase In clinical a lung FDA for of feedback survival analysis trial enrollment. of first trial, the metastatic and and in Phase global publishing in I the II ASPIRE registration opening our overall we enrolling as anticipate Phase in XXXX our XXXX trial well summary, non-small opening the pancreatic pancreatic EMA
have Panbela. year-to-date look creation XXXX. strives and quarter second progress and to forward We significant continued in marked clinical for development value The
our I over Sue now Sue? discuss to call will the turn to financial results.
